• A Business to Business strategy - Pharnext licenses new therapeutic solutions (Pleodrugs™) the latest at the end of phase II clinical trial to industrial partners. License agreements can be signed at different stage of the R&D process with risk sharing. Terms of the license are in line with normal practices in the biotechnology industry.
• Strategic R&D partnerships can be also considered on Pharnext ongoing early stage program, and on new program focusing on new indication of interest for the industrial partner.

Would you like to have any further information, please fee free to contact us